Drugs / Cobitolimod
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05404074 | Nov 2021 → Oct 2022 | ulcerative colitis | InDex Pharmaceuticals | Unknown | No outcome recorded |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT03178669 | Jun 2017 → Aug 2019 | ulcerative colitis | InDex Pharmaceuticals | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT04985968 | Nov 2021 → Dec 2023 | ulcerative colitis | InDex Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01493960 | Dec 2011 → Jun 2013 | ulcerative colitis | InDex Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cobitolimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05404074 ↗ |
| Action | Activate | “The Toll-like-receptor 9 (TLR-9) agonist cobitolimod” PMID 30120066 ↗ Jun 2018 |
| Modality | Oligonucleotide (other) | “modified single strand DNA-based synthetic oligodeoxyribonucleotide” NCT01493960 ↗ |
| Route | Rectal | “30 mg rectal dose at week 0 and 4” NCT01493960 ↗ |
| Target | TLR9 | “targeting the Toll-like receptor 9 (TLR9)” NCT01493960 ↗ |